Osteomyelitis is usually treated with systemic antibiotics for prolonged periods of time. These therapies are often unsuccessful with an increase in complication risk to the patient. The development of local antibiotic carriers which are mechanically stable, and can degrade slowly are needed clinically to treat the large number of cases of osteomyelitis seen in a hospital setting. Tricalcium phosphate has been shown to deliver effect concentrations of various agents in a sustained manner over prolonged periods of time both in vitro and in vivo. The objective of this study was to design a tricalcium phosphate carrier to effectively deliver tobramycin to treat a Staphylococcus aureus infection in a rat femoral osteotomy model over a seven day period, and compare the bone response to animals receiving only a femoral osteotomy with a Staphylococcus aureus infection and no treatment. Active osteomyelitis with bone loss was seen in animals with infection only. The presence of an inflammatory fibrous infiltrate was also evident in this group of animals. Administration of tobramycin via the TCPL carrier was able to reduce the associated bone loss and fibrous inflammatory filtrate. The carrier was able to deliver effective therapeutic levels of tobramycin and has the potential to be formulated to release the drug components for short or long durations by modifying the physiochemical parameters of the device.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Osteomyelitis is usually treated with systemic antibiotics for prolonged periods of time. These therapies are often unsuccessful with an increase in complication risk to the patient. The development of local antibiotic carriers which are mechanically stable, and can degrade slowly are needed clinically to treat the large number of cases of osteomyelitis seen in a hospital setting.
View Article and Find Full Text PDFHistological and radiographic comparison of allograft substitutes using a continuous delivery model in segmental defects.
Biomed Sci Instrum
June 2007
School of Medicine, School of Graduate Studies in Health Sciences, Department of Orthopaedic Surgery and Rehabilitation, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Demineralized bone matrix (DBM) has been shown to possess osteoinductive capability and one of the specific bone morphogenetic proteins (BMPs) found within DBM that has been attributed with this osteoinductive ability is BMP-7, also known as osteogenic protein-1 (OP-1). The specific aims of this study were (1) to compare the treatment of segmental bone defects with OP-l and DBM in a rat femur model and (2) to determine the effects of the two treatments given at high and low doses via sustained release drug delivery. Animals in Group 1 acted as the control and Group 2 had a created segmental defect with plating and placement of a calcined tricalcium phosphate lysine (TCPL) capsule containing antibiotic (sham).
View Article and Find Full Text PDFTargeted sustained delivery of tobramycin at the site of a femoral osteotomy.
Biomed Sci Instrum
July 2006
University of Mississippi Medical Center, Jackson, MS 39216, USA.
Complex fractures are difficult to manage because of the increased risk of secondary infection. Traditional treatments include debridment and local administration of antibiotics. Local antibiotic therapy is a safe technique resulting in high local concentration of antibiotics with minimal systemic levels.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!